Actions

Flow cytometry:ETP-ALL and The flow cytometric diagnosis of AML: Difference between pages

From haematologyetc.co.uk

(Difference between pages)
No edit summary
 
No edit summary
 
Line 1: Line 1:
----
----
<div style="width: 200px">
<div style="width: 200px">
{| class="wikitable" style="border-left:solid 5px green;border-right:solid 5px green;border-top:solid 5px black;border-bottom:solid 5px black; font-size:90%; color:navy"
{| class="wikitable" style="border-left:solid 5px green;border-right:solid 5px green;border-top:solid 5px black;border-bottom:solid 5px black; font-size:90%; color:navy"
| colspan="1"''|[[The flow cytometric diagnosis of AML|Return to previous page]]''
| colspan="1"''|[[Flow Cytometry|Return to previous page]]''
|}
|}
</div>
</div>
Line 8: Line 9:
--------
--------


The ETP-ALL/LBL
<div style="width: 100%">
{| class="wikitable" style="border-style: solid; border-width: 5px; color:black"
|colspan="1" style = "font-size:90%; color:black; background: #bcd4e6"|'''1. The immunophenotype of the blast cells should be consistent with their "primitive" nature'''
|}
</div>
 
[[Image:AML M1.png|110px]]
</br></br><span style="font-size:90%;">Assigning primitive nature in most cases is straightforward, but some sun-types of AML may present difficulties.</span>
 
<div style="width: 95%; font-size:90%;">
{| class="wikitable" style="border-style: solid; border-width: 4px; color:black"
!colspan="1" style = "background:#ddeee1; border:solid; border-width: 3px;"|<span style="font-size:90%;">'''Demonstrating primitive phenotype in AML'''</span></br>
|-
!colspan="1" style = "background:white; font-size:90%; border:solid; border-width: 1px; color:black"|'''Primitive phenotype:''' In most cases, cells of AML will demonstrate typical features of immature cells with: '''weak expression of CD45''', and expression of '''CD34''' and/or '''CD117'''</br>However, patterns are not always typical and difficult cases other markers of early differentiation may also help</br></br>[[Markers used to demonstrate primitive nature in AML|''Click for a more detailed table of markers associated with primitive phenotype'']]
|-
!colspan="1" style = "background:#ddeee1;border:solid"|<span style="font-size:90%;">'''Difficulties may occur where blast cells have significant maturation so their primitive nature may be less easy to demonstrate.'''</span></br>
|-
!colspan="1" style = "background:white; font-size:90%; border:solid; border-width: 1px;"|'''Difficulties:''' These are most frequently encountered in monocytic cases of AML, or in acute promyelocytic leukaemia (APL) (although occasionally in other types).</br></br>[[Atypical patterns of primitive marker expression in acute myeloid leukaemia|Click to see common patterns that may cause difficulty in assigning primitive phenotype]]
|-
|}
</div>
 


The immunophenotype of ETP-ALL requires careful consideration – this reflects that the condition was identified using gene expression profiling rather than by immunophenotype. Using immunophenotype to establish the diagnosis is therefore challenging and may underestimate the number of true cases.* and may not be easily separated from ALAL T/my
----
Or T-ALL


The approach presently advocated by WHO requires:
<div style="width: 100%">
1. Required expression: Cytoplasmic CD3 (may be heterogenous but should be expressed by ≥25% of blasts)
{| class="wikitable" style="border-style: solid; border-width: 5px; color:black"
2. Required expression: One or more myeloid antigen (CD11b, CD13, CD33, CD65, CD117) and/or stem cell antigens (CD34, HLA-DR)
|colspan="1" style = "font-size:90%; color:black; background:#bcd4e6"|'''2. The immunophenotype of the blast cells should allow myeloid lineage to be assigned'''
3. Required absence: CD3, CD1a and CD8 (<5% of blasts)
|}
4. Required absent/dim CD5 expression (<75% positive blasts)


Note that CD7 is consistently positive in ETP-ALL and does not count as a stem cell antigen in this context
[[Image:AML M2.png|130px]] 
*CD4 may have the same pattern




The ETP-ALL immunophenotype may also be established by immunohistochemistry.
<span style="font-size:90%;">The criteria to assign myeloid lineage in AML have been established, two alternative sets of criteria may be used (although most cases will meet both):


*T-ALL cases that have an immunophenotype similar to ETP-ALL but where CD5 is expressed (≥75% of blasts) may be designated as “near-ETP-ALL”, but the clinical implications of such a designation remain unclear.
<div style="width: 95%; font-size:90%;">
{| class="wikitable" style="border-style: solid; border-width: 4px; color:black"
!colspan="1" style = "background:#ddeee1; border:solid; border-width: 3px;"|<span style="font-size:90%;">'''Pattern A: AML diagnosis based on lineage-defining markers'''</span></br>
|-
!colspan="1" style = "background:white; border:solid; border-width: 1px; color:black"|A myeloid lineage-defining marker pattern is present '''and''' no lineage-defining markers of T or B cells are present</br>
<span style="font-size:90%;">[[Flow cytometry: Myeloid-defining markers|Click to view table of criteria]]</span>
|-
!colspan="1" style = "background:#ddeee1;border:solid"|<span style="font-size:90%;">'''Pattern B: AML diagnosis based on lineage-associated marker patterns'''</span></br>
|-
!colspan="1" style = "background:white; border:solid; border-width: 1px;"|At least two myeloid lineage-associated markers are present '''and''' there are no lineage defining markers of T or B cells '''and''' no more than one T-cell or B-cell lineage-associated marker is present</br>
<span style="font-size:90%;">[[Myeloid lineage-associated markers|Click to view table of criteria]]</span>
|}
</div>




Distinction from mixed-phenotype acute leukaemia (MPAL) requires that MPO is not expressed - in this context of ETP-ALL the WHO advocate a threshold of <3% to define negative myeloperoxidase expression (by cytochemistry or flow cytometry). This threshold is different from that of T/myeloid MPAL so may not be optimal but is retained at present.
----
 
<div style="width: 100%">
{| class="wikitable" style="border-style: solid; border-width: 5px; color:black"
|colspan="1" style = "font-size:90%; color:black; background:#bcd4e6"|'''3. Alternative diagnoses should be considered and excluded'''
|}
[[Image:Lymphoblast.png|110px]]
</div>
<span style="font-size:90%;"></br>In some cases lineage may be unclear - in such cases it is important to consider possible alternative diagnoses</span></br>
 
 
<span style="font-size:90%;">Alternative potential diagnoses in difficult cases:</span>
 
<div style="width: 95%; font-size:95%;">
{| class="wikitable" style="border-style: solid; border-width: 4px; color:black"
!colspan="2" style = "background:#ddeee1;border:solid"|<span style="font-size:90%;">'''Mixed Phenotype Acute Leukaemia''' (MPAL)</span>
|-
!colspan="2" style = "background:white;border:solid; font-size:90%;;"|'''Consider MPAL:''' Where myeloid lineage can be assigned based on '''lineage-specific''' patterns '''but''' the cells also have marker patterns that meet the criteria to assign T or B cell lineage.</br></br>[[Flow cytometry:MPAL|''Click for diagnostic criteria of MPAL'']]
|-
!colspan="2" style = "background:#ddeee1;border:solid"|'''Acute Undifferentiated Leukaemia''' (AUL)
|-
!colspan="2" style = "background:white; border:solid; font-size:90%;"|'''Consider AUL:''' In cases where the evidence is insufficient to assign myeloid lineage '''and''' there is insufficient evidence to assign to T-cell or B-cell lineage </br></br>[[Flow cytometry:AUL|''Click for diagnostic criteria of AUL'']]
|-
!colspan="2" style = "background:#ddeee1;border:solid"|'''Acute Leukaemia of ambiguous lineage not otherwise sepcified''' (ALAL-NOS)
|-
!colspan="2" style = "background:white; border:solid; font-size:90%;"|'''Consider ALAL-NOS:''' if classification to specific lineage is not possible '''but''' blast cells cannot be classed as AUL or MPAL.</br></br>[[Flow cytometry:ALAL-NOS|''This is most often a useful provisional diagnosis - click here for details'']]</br>
|-
!colspan="2" style = "background:#ddeee1;border:solid"|''' Early T-cell precursor acute lymphoblastic leukaemia''' (ETP-ALL)
|-
!colspan="2" style = "background:white; border:solid; font-size:90%;"| This disorder has diagnostic criteria sufficient to assign T cell lineage (cCD3 is expressed) but may express myeloid-associated antigens cases may share features with MPAL M/T</br>[[Flow cytometry:ETP-ALL|''Click for diagnostic criteria of ETP-ALL'']]
|-
!colspan="2" style = "background:#ddeee1;border:solid"|'''Blastic plasmacytoid dendritic cell neoplasm''' (BPDCN)
|-
!colspan="2" style = "background:white; border:solid; font-size:90%;"|'''Consider BPDCN:''' Generally in cases that resemble AUL (rarely AML), most often with skin rash. A specific marker profile should be sought: expression of bright CD4 and/or CD56 is expected. CD33 is frequently expressed but other myeloid markers are less frequent and MPO and CD34 should be absent. Look for specific additional markers as described in the diagnostic criteria.</br></br>[[Flow cytometry:BPDCN|''Click for diagnostic criteria of BPDCN'']]
|}
</br>
 
</br>
<span style="font-size:90%;">*'''NOTE''' Some "non-lineage" markers are frequently expressed in AML and may be associated with specific AML subtypes, these do not necessarily indicate mixed phenotype ([[Table of frequent aberrant markers in AML|Click here for further detail]]). Other features should give concern for alternative diagnosis (see the table below more detailed guidance).
 
----

Revision as of 11:46, 16 January 2024



1. The immunophenotype of the blast cells should be consistent with their "primitive" nature

AML M1.png

Assigning primitive nature in most cases is straightforward, but some sun-types of AML may present difficulties.

Demonstrating primitive phenotype in AML
Primitive phenotype: In most cases, cells of AML will demonstrate typical features of immature cells with: weak expression of CD45, and expression of CD34 and/or CD117
However, patterns are not always typical and difficult cases other markers of early differentiation may also help

Click for a more detailed table of markers associated with primitive phenotype
Difficulties may occur where blast cells have significant maturation so their primitive nature may be less easy to demonstrate.
Difficulties: These are most frequently encountered in monocytic cases of AML, or in acute promyelocytic leukaemia (APL) (although occasionally in other types).

Click to see common patterns that may cause difficulty in assigning primitive phenotype



2. The immunophenotype of the blast cells should allow myeloid lineage to be assigned

AML M2.png


The criteria to assign myeloid lineage in AML have been established, two alternative sets of criteria may be used (although most cases will meet both):

Pattern A: AML diagnosis based on lineage-defining markers
A myeloid lineage-defining marker pattern is present and no lineage-defining markers of T or B cells are present

Click to view table of criteria

Pattern B: AML diagnosis based on lineage-associated marker patterns
At least two myeloid lineage-associated markers are present and there are no lineage defining markers of T or B cells and no more than one T-cell or B-cell lineage-associated marker is present

Click to view table of criteria



3. Alternative diagnoses should be considered and excluded

Lymphoblast.png


In some cases lineage may be unclear - in such cases it is important to consider possible alternative diagnoses


Alternative potential diagnoses in difficult cases:

Mixed Phenotype Acute Leukaemia (MPAL)
Consider MPAL: Where myeloid lineage can be assigned based on lineage-specific patterns but the cells also have marker patterns that meet the criteria to assign T or B cell lineage.

Click for diagnostic criteria of MPAL
Acute Undifferentiated Leukaemia (AUL)
Consider AUL: In cases where the evidence is insufficient to assign myeloid lineage and there is insufficient evidence to assign to T-cell or B-cell lineage

Click for diagnostic criteria of AUL
Acute Leukaemia of ambiguous lineage not otherwise sepcified (ALAL-NOS)
Consider ALAL-NOS: if classification to specific lineage is not possible but blast cells cannot be classed as AUL or MPAL.

This is most often a useful provisional diagnosis - click here for details
Early T-cell precursor acute lymphoblastic leukaemia (ETP-ALL)
This disorder has diagnostic criteria sufficient to assign T cell lineage (cCD3 is expressed) but may express myeloid-associated antigens cases may share features with MPAL M/T
Click for diagnostic criteria of ETP-ALL
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Consider BPDCN: Generally in cases that resemble AUL (rarely AML), most often with skin rash. A specific marker profile should be sought: expression of bright CD4 and/or CD56 is expected. CD33 is frequently expressed but other myeloid markers are less frequent and MPO and CD34 should be absent. Look for specific additional markers as described in the diagnostic criteria.

Click for diagnostic criteria of BPDCN



*NOTE Some "non-lineage" markers are frequently expressed in AML and may be associated with specific AML subtypes, these do not necessarily indicate mixed phenotype (Click here for further detail). Other features should give concern for alternative diagnosis (see the table below more detailed guidance).